TAVI与SAVR试验死亡率:Kaplan-Meier个体患者数据汇总Meta分析
该汇总Meta分析基于6项随机对照试验共6367例受试者(TAVI 3252例、SAVR 3115例),从已发表Kaplan-Meier曲线重建个体患者时间-事件数据,评估TAVI与SAVR对长期全因死亡率的影响。地标分析显示TAVI组术后第一年死亡风险显著更低(风险分层HR 0.85,95%CI 0.73-0.99;P=0.04),但40个月后风险比反转(HR 1.31,95%CI 1.01-1.68;P=0.04),转而支持SAVR。
要点
- TAVI术后第一年全因死亡风险低于SAVR(HR 0.85)。
- 40个月后死亡风险比反转,SAVR优于TAVI(HR 1.31)。
- 传统Meta分析方法因未处理异质性与时间变化效应而存在偏倚。
核心结论
- TAVI与SAVR试验中的死亡率受治疗方式影响并呈现时间变化效应:TAVI在术后最初数月生存更优,而40个月后成为全因死亡的危险因素。
研究设计与样本
- 汇总Meta分析,基于Kaplan-Meier曲线重建个体患者时间-事件数据。
- 检索Medline、Embase、Cochrane数据库及专业网站,纳入6项比较TAVI与SAVR的试验,共6367例受试者(TAVI 3252例、SAVR 3115例)。
- 采用随机效应Cox模型在地标框架及全参数模型下比较治疗,并比较传统Meta分析工具与估计个体患者数据Meta分析。
主要发现
- 地标分析中,术后第一年TAVI组死亡发生率显著低于SAVR组(风险分层HR 0.85,95%CI 0.73-0.99;P=0.04)。
- 40个月后风险比反转,支持SAVR优于TAVI(风险分层HR 1.31,95%CI 1.01-1.68;P=0.04)。
- 全参数时间-事件模型同样证实风险比的时间变化趋势。
- 传统Meta分析工具因未捕捉异质性和时间变化效应而存在偏倚。
临床怎么用
- 解读TAVI与SAVR长期死亡率比较时需考虑时间变化效应,不宜仅凭单一时点的汇总HR下结论。
- 术后早期(第一年)TAVI生存优势与40个月后SAVR优势并存,提示需结合患者预期寿命与随访时长个体化选择术式。
局限性
- 原文摘要未报告各试验的具体随访时长、患者基线风险构成及异质性统计量,相关解读受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This meta-analysis of Kaplan-Meier-estimated individual patient data was designed to evaluate the effects of transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) on the long-term all-cause mortality rate, to examine the potential time-varying effect and to model their hazard ratios (HRs) over time. Moreover, we sought to compare traditional meta-analytic tools and estimated individual patient data meta-analyses. METHODS: Trials comparing TAVI versus SAVR were identified through Medline, Embase, Cochrane databases and specialist websites. The primary outcome was death from any cause at follow-up. Enhanced secondary analyses of survival curves were performed estimating individual patient time-to-event data from published Kaplan-Meier curves. Treatments were compared with the random effect Cox model in a landmark framework and fully parametric models. RESULTS: We identified 6 eligible trials that included 6367 participants, randomly assigned to undergo TAVI (3252) or SAVR (3115). According to the landmark analysis, the incidence of death in the first year after implantation was significantly lower in the TAVI group [risk-profile stratified HR 0.85, 95% confidence interval (CI) 0.73-0.99; P = 0.04], whereas there was a reversal of the HR after 40 months (risk-profile stratified HR 1.31, 95% CI 1.01-1.68; P = 0.04) favouring SAVR over TAVI. This time-varying trend of HRs was also confirmed by a fully parametric time-to-event model. Traditional meta-analytic tools were shown to be biased because they did not intercept heterogeneity and the time-varying effect. CONCLUSIONS: The mortality rates in trials of TAVI versus SAVR are affected by treatments with a time-varying effect. TAVI is related to better survival in the first months after implantation whereas, after 40 months, it is a risk factor for all-cause mortality.
引用
- Barili F, Freemantle N, Pilozzi Casado A, et al. Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data. Eur J Cardiothorac Surg. 2020. PMID: 32236543. doi:10.1093/ejcts/ezaa087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。